Upregulation of Cathepsin D in the caudate nucleus of primates with experimental parkinsonism

Molecular Neurodegeneration

Volumn 6, Issue 1, 2011, Pages

  Yelamanchili, Sowmya V ^a   Chaudhuri, Amrita ^a   Flynn, Claudia T ^b   Fox, Howard S ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

apoptosis; cathepsin; caudate; MPTP; neurodegeneration; nonhuman primate; Parkinson's; striatum

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CASPASE; CATHEPSIN D;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRAIN TISSUE; CAUDATE NUCLEUS; COGNITION; DISEASE COURSE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LYSOSOME; MALE; MOTOR COORDINATION; NERVE CELL; NERVE CELL NECROSIS; NEUROBLASTOMA CELL; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; RAT; RHESUS MONKEY; UPREGULATION;

MACACA MULATTA; PRIMATES;

EID: 79960566099     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-6-52     Document Type: Article

References (40)

1. Parkinson's disease: mechanisms and models. Dauer W, Przedborski S, Neuron 2003 39 889 909 10.1016/S0896-6273(03)00568-3 12971891 (Pubitemid 37130207)
2. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E, Obeso JA, Lancet Neurol 2009 8 1128 1139 10.1016/S1474-4422(09)70293-5 19909911
3. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Langston JW, Ann Neurol 2006 59 591 596 10.1002/ana.20834 16566021
4. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F, J Neurol Sci 1973 20 415 455 10.1016/0022-510X(73)90175-5 4272516
5. Temporal dynamics of basal ganglia under-recruitment in Parkinson's disease: transient caudate abnormalities during updating of working memory. Marklund P, Larsson A, Elgh E, Linder J, Riklund KA, Forsgren L, Nyberg L, Brain 2009 132 336 346 19036762
6. Executive dysfunction in Parkinson's disease is associated with altered pallidal-frontal processing. Dirnberger G, Frith CD, Jahanshahi M, Neuroimage 2005 25 588 599 10.1016/j.neuroimage.2004.11.023 15784438 (Pubitemid 40387341)
7. Abnormal basal ganglia outflow in Parkinson's disease identified with PET. Implications for higher cortical functions. Owen AM, Doyon J, Dagher A, Sadikot A, Evans AC, Brain 1998 121 Pt 5 949 965 9619196 (Pubitemid 28220900)
8. The role of the striatum and hippocampus in planning: a PET activation study in Parkinson's disease. Dagher A, Owen AM, Boecker H, Brooks DJ, Brain 2001 124 1020 1032 10.1093/brain/124.5.1020 11335704 (Pubitemid 32458514)
9. Cortical activity in Parkinson's disease during executive processing depends on striatal involvement. Monchi O, Petrides M, Mejia-Constain B, Strafella AP, Brain 2007 130 233 244 17121746 (Pubitemid 46026238)
10. Organelle-specific initiation of cell death pathways. Ferri KF, Kroemer G, Nat Cell Biol 2001 3 255 263 10.1038/ncb1101-e255 11715037 (Pubitemid 34428737)
11. Proteolytic mechanisms in necrotic cell death and neurodegeneration. Artal-Sanz M, Tavernarakis N, FEBS Lett 2005 579 3287 3296 10.1016/j.febslet. 2005.03.052 15943973 (Pubitemid 40804676)
12. Proteases of human brain. Pope A, Nixon RA, Neurochem Res 1984 9 291 323 10.1007/BF00963980 6377107 (Pubitemid 14086519)
13. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH, Neurobiol Dis 2009 35 385 398 10.1016/j.nbd.2009.05.023 19505575
14. Cathepsin D - many functions of one aspartic protease. Benes P, Vetvicka V, Fusek M, Crit Rev Oncol Hematol 2008 68 12 28 10.1016/j.critrevonc.2008.02. 008 18396408
15. Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain. Cataldo AM, Nixon RA, Proc Natl Acad Sci USA 1990 87 3861 3865 10.1073/pnas.87.10.3861 1692625 (Pubitemid 20182559)
16. Up-regulation of the lysosomal system in experimental models of neuronal injury: implications for Alzheimer's disease. Adamec E, Mohan PS, Cataldo AM, Vonsattel JP, Nixon RA, Neuroscience 2000 100 663 675 10.1016/S0306-4522(00) 00281-5 11098128
17. Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism. Kurlan R, Kim MH, Gash DM, Mov Disord 1991 6 111 118 10.1002/mds.870060205 2057003
18. Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey. Imbert C, Bezard E, Guitraud S, Boraud T, Gross CE, J Neurosci Methods 2000 96 71 76 10.1016/S0165-0270(99) 00184-3 10704673 (Pubitemid 30125866)
19. Degradation of neurofilament proteins by purified human brain cathepsin D. Nixon RA, Marotta CA, J Neurochem 1984 43 507 516 10.1111/j.1471-4159.1984. tb00928.x 6429280 (Pubitemid 14093581)
20. Attention and executive function deficits in chronic low-dose MPTP-treated non-human primates. Decamp E, Schneider JS, Eur J Neurosci 2004 20 1371 1378 10.1111/j.1460-9568.2004.03586.x 15341609 (Pubitemid 39233588)
21. Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Schneider JS, Kovelowski CJ, Brain Res 1990 519 122 128 10.1016/0006-8993(90)90069-N 2397401 (Pubitemid 20199679)
22. Oxidative stress causes relocation of the lysosomal enzyme cathepsin D with ensuing apoptosis in neonatal rat cardiomyocytes. Roberg K, Ollinger K, Am J Pathol 1998 152 1151 1156 9588882 (Pubitemid 28221866)
23. Lysosomal release of cathepsin D precedes relocation of cytochrome c and loss of mitochondrial transmembrane potential during apoptosis induced by oxidative stress. Roberg K, Johansson U, Ollinger K, Free Radic Biol Med 1999 27 1228 1237 10.1016/S0891-5849(99)00146-X 10641715 (Pubitemid 30001483)
24. The lysosomal protease cathepsin D mediates apoptosis induced by oxidative stress. Kagedal K, Johansson U, Ollinger K, FASEB J 2001 15 1592 1594 11427496
25. Cellular injury induced by oxidative stress is mediated through lysosomal damage. Ollinger K, Brunk UT, Free Radic Biol Med 1995 19 565 574 10.1016/0891-5849(95)00062-3 8529915
26. Translocation of lysosomal cathepsin D caused by oxidative stress or proteasome inhibition in primary cultured neurons and astrocytes. Miura Y, Sakurai Y, Hayakawa M, Shimada Y, Zempel H, Sato Y, Hisanaga S, Endo T, Biol Pharm Bull 33 22 28
27. Oxidative stress in Parkinson's disease. Jenner P, Ann Neurol 2003 53 Suppl 3 26 36 discussion S36-28 12666096
28. Lysosomes in cell death. Guicciardi ME, Leist M, Gores GJ, Oncogene 2004 23 2881 2890 10.1038/sj.onc.1207512 15077151 (Pubitemid 38638850)
29. Lysosomal membrane permeabilization and cathepsin release is a Bax/Bak-dependent, amplifying event of apoptosis in fibroblasts and monocytes. Oberle C, Huai J, Reinheckel T, Tacke M, Rassner M, Ekert PG, Buellesbach J, Borner C, Cell Death Differ 2010 17 1167 1178 10.1038/cdd.2009.214 20094062
30. Apoptosis in Parkinson's disease: signals for neuronal degradation. Tatton WG, Chalmers-Redman R, Brown D, Tatton N, Ann Neurol 2003 53 Suppl 3 61 70 discussion S70-62 12666099
31. In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells. Briozzo P, Morisset M, Capony F, Rougeot C, Rochefort H, Cancer Res 1988 48 3688 3692 3378211
32. Cathepsin D overexpressed by cancer cells can enhance apoptosis-dependent chemo-sensitivity independently of its catalytic activity. Beaujouin M, Liaudet-Coopman E, Adv Exp Med Biol 2008 617 453 461 10.1007/978-0-387-69080-3- 44 18497069
33. Pro-cathepsin D interacts with the extracellular domain of the beta chain of LRP1 and promotes LRP1-dependent fibroblast outgrowth. Beaujouin M, Prebois C, Derocq D, Laurent-Matha V, Masson O, Pattingre S, Coopman P, Bettache N, Grossfield J, Hollingsworth RE, et al. J Cell Sci 2010 123 3336 3346 10.1242/jcs.070938 20826454
34. Cathepsin D plays a crucial role in the trimethyltin-induced hippocampal neurodegeneration process. Ceccariglia S, D'Altocolle A, Del Fa A, Pizzolante F, Caccia E, Michetti F, Gangitano C, Neuroscience 2011 174 160 170 21111789
35. Altered expression and distribution of cathepsins in neuronopathic forms of Gaucher disease and in other sphingolipidoses. Vitner EB, Dekel H, Zigdon H, Shachar T, Farfel-Becker T, Eilam R, Karlsson S, Futerman AH, Hum Mol Genet 2010 19 3583 3590 10.1093/hmg/ddq273 20616152
36. Intraneuronal amyloid beta oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. Umeda T, Tomiyama T, Sakama N, Tanaka S, Lambert MP, Klein WL, Mori H, J Neurosci Res 2011 89 1031 1042 10.1002/jnr.22640 21488093
37. Lysosomal membrane permeabilization in cell death. Boya P, Kroemer G, Oncogene 2008 27 6434 6451 10.1038/onc.2008.310 18955971
38. Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. Sevlever D, Jiang P, Yen SH, Biochemistry 2008 47 9678 9687 10.1021/bi800699v 18702517
39. Controlled and behaviorally relevant levels of oral ethanol intake in rhesus macaques using a flavorant-fade procedure. Katner SN, Flynn CT, Von Huben SN, Kirsten AJ, Davis SA, Lay CC, Cole M, Roberts AJ, Fox HS, Taffe MA, Alcohol Clin Exp Res 2004 28 873 883 10.1097/01.ALC.0000128895.99379.8C 15201630 (Pubitemid 38780565)
40. Enrichment and persistence of virus-specific CTL in the brain of simian immunodeficiency virus-infected monkeys is associated with a unique cytokine environment. Marcondes MC, Burdo TH, Sopper S, Huitron-Resendiz S, Lanigan C, Watry D, Flynn C, Zandonatti M, Fox HS, J Immunol 2007 178 5812 5819 17442965 (Pubitemid 46674378)